# OnCo record resectable-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/resectable-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "resectable-pdac" ;
  schema:name "Resectable pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "Resectable pancreatic cancer"@en, "Operable pancreatic cancer"@en, "Early-stage PDAC"@en, "Stage I to II pancreatic adenocarcinoma"@en ;
  schema:description "Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."@en ;
  schema:url <https://onco.cc/cancers/resectable-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/ipmn-cystic-precursors/>, <https://onco.cc/cancers/ampullary/> ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/eras-perioperative-nutrition/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/eli-002-7p/> ;
  onco:companies <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/elicio-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/gbrca-mutation/> ;
  onco:trials <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct06538857/>, <https://onco.cc/trials/nct04969731/>, <https://onco.cc/trials/amplify-7p/> ;
  onco:people <https://onco.cc/people/thierry-conroy/>, <https://onco.cc/people/marc-besselink/>, <https://onco.cc/people/vinod-balachandran/>, <https://onco.cc/people/jurgen-weitz/>, <https://onco.cc/people/richard-schulick/>, <https://onco.cc/people/eileen-oreilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/>, <https://onco.cc/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/> ;
  onco:pipeline <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/nct06538857/>, <https://onco.cc/trials/nct04969731/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/>, <https://onco.cc/ideas/idea-bio2-prehabilitation-standard/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/technologies/ct/> .